EPIGENETIC CHANGES - HISTONE 3 PHOSPHORYLATION - EPITHELIAL OVARIAN TUMORS

Area of Science:

• Epigenetics and molecular biology
• Oncology and pathology

Background:

• Histone modifications, such as phosphorylation, are key epigenetic changes.
• Phosphohistone-H3 (pHH3) antibodies target phosphorylated serine residues on histone H3.
• pHH3 is traditionally used to identify cells in late G2 and M phases, indicating proliferation.

Purpose of the Study:

• To investigate the distribution of pHH3 in epithelial ovarian tumors.
• To analyze the relationship between pHH3 expression and established biomarkers (ER, PR, Ki67, p53, BCL2).
• To evaluate pHH3 as a potential marker for proliferation and malignancy in ovarian cancer.

Main Methods:

• Postoperative tissue samples from 160 ovarian tumor patients were analyzed.
• Standard immunohistochemistry was employed to detect pHH3, ER, PR, Ki67, p53, and BCL2.
• Expression levels and correlations between markers were statistically evaluated.

Main Results:

• pHH3 expression showed a negative association with ER, PR, and BCL2.
• A positive correlation was observed between pHH3 and Ki67, and mutant p53 expression (p<0.05).
• pHH3 was detected in Ki67-negative cases and its expression increased with higher malignancy grades.

Conclusions:

• pHH3 expression is linked to proliferation and malignancy in epithelial ovarian tumors.
• pHH3 may serve as an additional marker for assessing proliferation and malignancy potential.
• Further research could establish pHH3's role in ovarian cancer prognostication.